Longitudinal FDG-PET scan study of brain changes in mice with cancer-induced bone pain and after morphine analgesia

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Advanced cancer often causes significant physical and psychological suffering.
• Morphine is a primary analgesic for cancer pain, but its effects on brain metabolism during bone pain are unclear.
• Understanding these effects is crucial for optimizing cancer pain management.

Purpose of the Study:

• To investigate the whole-brain metabolic activity changes associated with cancer-induced bone pain.
• To elucidate the neural correlates of morphine's analgesic effects in this condition.
• To explore the brain regions affected by morphine during cancer pain.

Main Methods:

• 4T1 mouse breast cancer cells were injected into the femur of BALB/c mice.
• Cancer-induced bone pain was assessed through behavioral deficits and hypersensitivity.
• Serial 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) was used to measure brain glucose metabolism before and during cancer pain and morphine treatment.

Main Results:

• Cancer-induced bone pain increased glucose uptake in the insular cortex and hypothalamus, while decreasing retrosplenial cortex activity.
• Morphine treatment reversed insular cortex and hypothalamus activation.
• Morphine also activated the amygdala and rostral ventromedial medulla, and suppressed anterior cingulate cortex activity.

Conclusions:

• Cancer-induced bone pain involves significant inflammatory and affective components, as indicated by hypothalamic and insular cortical activation.
• Morphine's analgesic effects in cancer bone pain may involve both descending inhibitory and facilitatory pathways.
• These findings provide a deeper understanding of morphine's mechanism of action in managing cancer pain.